STAAR Surgical Company

$ 29.12 -0.34 %

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

CEO: Warren Foust - https://www.staar.com

Price objectif

$29.33 0.72 %

Recommandation

Hold

DCF

$ -0.35

Loading data...

STAA vs S&P500

Loading data...

No data available.

Quick ratio

4.31

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-69.33

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.42

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-6.07 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-1.26 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

9.89

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.11

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-1.10

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
9.59 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.16 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.08 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.